Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVT 201

Next Previous
Drug Profile

EVT 201

Alternative Names: EVT-201

Latest Information Update: 09 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Evotec AG; Zhejiang Jingxin Pharmaceutical
  • Class Sleep disorder therapies
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insomnia

Most Recent Events

  • 12 Aug 2015 Phase-II development is ongoing in China
  • 31 Dec 2014 Zhejiang Jingxin Pharmaceuticals initiates enrolment in a phase I multi-dose trial in China before December 2014
  • 12 Nov 2014 Phase-II clinical trials in Insomnia in China (PO) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top